La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kaken Pharmaceutical Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Hiroyuki Horiuchi

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.3yrs
Proprietà del CEO	0.02%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Hiroyuki Horiuchi

4.3yrs

Mandato

Mr. Hiroyuki Horiuchi serves as Director of Kaken Pharmaceutical Co. Ltd. since June 2016 and its President since June 2020. He was Chief Officer of Marketing & Sales of Kaken Pharmaceutical Co. Ltd.since...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Hiroyuki Horiuchi	President & Representative Director	8.3yrs	Nessun dato	0.020% ¥ 29.6m
Masashi Suzudo	GM of Corporate Planning & Coordination Department and Director	3.3yrs	Nessun dato	0.0084% ¥ 12.3m
Hirotoshi Endo	Outside Audit & Supervisory Board Member	5.3yrs	Nessun dato	Nessun dato
Yoshio Tanabe	Director	8.3yrs	Nessun dato	Nessun dato
Shoichiro Takagi	Independent Outside Director	4.3yrs	Nessun dato	0.0013% ¥ 1.9m
Minoru Ohta	Director	4.3yrs	Nessun dato	0.0040% ¥ 5.8m
Yasutomo Inoue	Independent Outside Director	3.3yrs	Nessun dato	0.00026% ¥ 379.0k
Naomi Doi	Standing Audit & Supervisory Board Member	6.3yrs	Nessun dato	Nessun dato
Kiyoko Kamibeppu	Independent Outside Director	5.3yrs	Nessun dato	0.0011% ¥ 1.5m
Masahiro Matsuura	Director	4.3yrs	Nessun dato	0.014% ¥ 20.8m
Hiroaki Matsumoto	Outside Audit & Supervisory Board Member	3.3yrs	Nessun dato	0.0011% ¥ 1.5m
Kazumori Ishiguro	Standing Audit & Supervisory Board Member	2.3yrs	Nessun dato	0.0050% ¥ 7.3m

4.3yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4521 sono considerati esperti (durata media dell'incarico 4.2 anni).

Kaken Pharmaceutical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥115 per share

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024

Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Consensus revenue estimates increase by 18%

Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Now 20% overvalued after recent price rise

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024

Third quarter 2024 earnings released: EPS: JP¥68.84 (vs JP¥85.00 in 3Q 2023)

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings released: EPS: JP¥41.28 (vs JP¥81.46 in 2Q 2023)

Upcoming dividend of JP¥75.00 per share at 4.2% yield

Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)

Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023

Kaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024

First quarter 2024 earnings released: EPS: JP¥66.98 (vs JP¥76.89 in 1Q 2023)

New minor risk - Dividend sustainability

Consensus EPS estimates fall by 26%, revenue upgraded

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥75.00 per share at 4.1% yield

Third quarter 2023 earnings released: EPS: JP¥84.99 (vs JP¥93.21 in 3Q 2022)

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

First quarter 2023 earnings released: EPS: JP¥76.89 (vs JP¥87.76 in 1Q 2022)

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 03, 2022

Kaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 30, 2022; Provides Second Quarter and Fiscal Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 350,000 shares, representing 0.92% for ¥1,500 million.

Less than half of directors are independent

Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of ARTham Therapeutics Inc for ¥5.5 billion.

Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire ARTham Therapeutics Inc.

Second quarter 2022 earnings released: EPS JP¥88.47 (vs JP¥87.95 in 2Q 2021)

Upcoming dividend of JP¥75.00 per share

First quarter 2022 earnings released: EPS JP¥87.76 (vs JP¥98.16 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥347 (vs JP¥495 in FY 2020)

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 500,000 shares, representing 1.3% for ¥2,500 million.

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 07, 2021

New 90-day high: JP¥4,220

Third quarter 2021 earnings released: EPS JP¥96.58 (vs JP¥154 in 3Q 2020)

New 90-day low: JP¥3,805

Price target lowered to JP¥3,800

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 03, 2021

Brickell Biotech, Inc. Announces Launch Date for Sofpironium Bromide Gel in Japan by Kaken Pharmaceutical Co., Ltd

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 05, 2020

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media